Ribavirin considerations in treatment optimization

Antiviral Therapy

Volumn 13, Issue SUPPL. 1, 2008, Pages 23-30

  Dusheiko, Geoffrey ^a   Nelson, David ^b   Reddy, K Rajender ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ANTIVIRAL ACTIVITY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 42149127046     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:225-230.
3. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002, June 10-12. Hepatology 2002; 36:S3-20.
4. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
5. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:897-903.
6. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996; 3:247-252.
7. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-598.
8. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477.
9. Zoulim F, Haem J, Ahmed SS, et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 1998; 5:193-198.
10. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006; 63:832-842.
11. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972.
12. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703-714.
13. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-1009.
14. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005; 107:165-171.
15. Domingo E, Escarmis C, Sevilla N, et al. Basic concepts in RNA virus evolution. FASEB J 1996; 10:859-864.
16. Eigen M, McCaskill J, Schuster P. The molecular quasi-species. Adv Chem Phys 1989; 75:149-263.
17. Eigen M, McCaskill J, Schuster P. Molecular quasi-species. J Phys Chem 1988; 92:6881-6891.
18. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA 2002; 99:13374-13376.
19. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007; 81:7732-7741.
20. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563.
21. Herrmann E, Sarrazin C. Hepatitis C-virus - viruskinetik und resistenzmechanismen [Hepatitis C-virus - virus kinetics and resistance mechanisms]. Z Gastroenterol 2004; 42:387-396.
22. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
23. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
24. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
25. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-1048.
26. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
27. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5:124-129.
28. Bain VG, Lee SS, Peltekian K, et al. Exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection: analysis of the Canadian PEGASYS Expanded Access Program. Hepatology 2006; 44:335A-336A.
29. Satoh T, Masumoto A. Accordion Index: a new tool for the prediction of the efficacy of peg-interferon-alpha-2b and ribavirin combination therapy for chronic hepatitis C. Hepatol Res 2007 Oct 10. Epub ahead of print. doi: 10.1111/j.1872-034X.2007.00272.x
30. Fried M, Jensen D, Rodriguez-Torres M, et al. Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (RBV) (COPEGUS) in patients with difficult-to-cure charcteristics. Hepatology 2006; 44 Suppl 1:314A.
31. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with Standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
32. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004.
33. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124:1711-1719.
34. McHutchison JG, Manns MP, Brown RS, Jr., Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102:880-889.
35. Spangler C, Han S, Morrissey Kwasny M, Cohen S, Jensen D. Early predictors of hemoglobin reduction during first four weeks of peginterferon alpha-2a/ribavirin therapy in chronic hepatitis C. DDW 2006; Abstract # T1834.
36. Reau N, Jensen D, Hadziyannis S, Messinger D, Fried M. Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day. Hepatology 2006; 44 Suppl1:338A.
37. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46:371-379.
38. United States Food and Drug Administration. FDA Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs). 9 March 2007. Available at: http://www.fda.gov/cder/drug/advisory/RHE2007.htm
39. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62:699-709.